Impact of non-pharmacological strategies on progression in Parkinson’s Disease and Cognitive Impairment.
Objective: to determine the Impact of non-pharmacological strategies on progression in Parkinson's Disease and Cognitive Impairment. Background: PD is the second most common neurodegenerative disorder,…The phenotypic spectrum and assessment of severity in patients of Spinocerebellar Ataxia-12.
Objective: To describe clinical phenotype, manifestations, and assess tremor severity using standard rating scale in genetically confirmed patients with SCA12. Background: Spinocerebellar Ataxia-12 (SCA12) occurs…Functional Neuroimaging and Follow up trends in Drug induced movement disorders.
Objective: To analyse the role of presynaptic dopaminergic imaging (TRODAT/ F Dopa PET) scans to predict long-term outcomes in patients of new onset parkinsonian symptoms…Correlation between dose of dopamine replacement therapy and King’s Parkinson’s Disease Pain Scale in Mexican Patients with Parkinson’s Disease
Objective: Investigate the relationship between the dose of dopamine replacement therapy (DRT) and pain severity as measured by the King's Parkinson's Disease Pain Scale (KPPS)…Clinical toolkits to improve conversations about Parkinson’s dementia
Objective: To co-produce, with people living with Parkinson’s and professionals, a pair of toolkits to improve conversations about Parkinson’s dementia in the clinic: one for…Improvement in spasticity-associated dressing- and hygiene-related disability in adults following treatment with incobotulinumtoxinA: a pooled analysis
Objective: To evaluate impact of incobotulinumtoxinA (incoA) on dressing- and hygiene-related disability (DRE and HYG) in adults with upper-limb spasticity (ULS) based on pooled data…Characteristics of cases in which stimulation was programmed for multiple targets in deep brain stimulation therapy for Parkinson’s disease.
Objective: To clarify the the clinical background of Parkinson's disease patients with DBS who received multiple stimulus targets. Background: Deep brain stimulation (DBS) is an…Transition among HD-ISS stages as an endpoint in clinical trials for HD
Objective: Investigate the time to the event of HD-ISS Stage 3 transition (functional change) as an endpoint for clinical trials in Huntington’s disease (HD) and…Teleprogramming Reduces the Time Needed to Optimize DBS Therapy: Results from the ROAM-DBS study
Objective: To present early outcomes from the ROAM-DBS (Deep Brain Stimulation) trial on the clinical efficacy of teleprogramming for DBS demonstrating more rapid improvement when…Caveats regarding a family with PD and LRRK2 mutations
Objective: To describe and discuss genetic considerations regarding a kindred with PD cases with similar clinical characteristics, some with identified mutations in the LRRK2 gene…
- « Previous Page
- 1
- …
- 486
- 487
- 488
- 489
- 490
- …
- 1734
- Next Page »
